Publikationen (231) Publikationen von María Pilar Garrido López

2024

  1. A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non-Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy

    European Oncology and Haematology, Vol. 20, Núm. 1, pp. 5-8

  2. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  3. Characteristics and Survival Outcomes of Patients with Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting

    JCO Precision Oncology, Vol. 8, Núm. 1

  4. Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

    Scientific Reports, Vol. 14, Núm. 1

  5. Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

    Journal of Medical Economics, Vol. 27, Núm. 1, pp. 1379-1387

  6. Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent

    Cancer Immunology, Immunotherapy, Vol. 73, Núm. 10

  7. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

  8. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  9. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

    ESMO Open, Vol. 9, Núm. 6

  10. Sesgo de género en la profesión médica en España

    XLIII Jornadas de Economía de la Salud. Políticas públicas para la salud: perspectivas desde la economía y la sanidad

  11. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

  12. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

  13. The sooner, the better: early clearance of plasma circulating tumor DNA in patients with advanced KRAS G12C mutant non-small cell lung cancer

    Translational Lung Cancer Research

  14. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

    Lung Cancer, Vol. 188

2023

  1. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study

    Clinical and Translational Oncology, Vol. 25, Núm. 1, pp. 283-291

  2. A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

    Journal of Clinical Pharmacology, Vol. 63, Núm. 5, pp. 583-592

  3. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

    The oncologist, Vol. 28, Núm. 3, pp. 258-267

  4. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  5. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

    ESMO Open, Vol. 8, Núm. 2

  6. Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 25, 5, (1252-1267), 10.1007/s12094-022-03046-9)

    Clinical and Translational Oncology